Hepatitis C virus (HCV) impairs glucose homoestasis, thus influences its clinical picture and prognosis. Adult patients with CHC were divided into 2 groups; Diabetic patients, and Non diabetic patients serving as control group. All patients were subjected to thorough clinical evaluation, basic biochemical laboratory tests including fasting blood glucose/glycosylated haemoglobin (HbA1C), and virologic assay. They were treated with various combined DAAs, and were monitored during, at and after end of treatment. Diabetic patients constituted 9.85 % of CHC, and had generally worse laboratory tests (significantly higher transaminases, platelet count, Fib4 and hepatic steatosis) than non diabetic patients, and a less sustained virologic response (SVR) (significantly in Sofosbuvir (SOF) + pegylated interferon (PegIFN) + ribavirin (RBV), SOF + RBV, SOF + daclatasvir (DAC)). Although DM did not play a significant influence on SVR, yet Fib4 and SOF + RBV + PEG-IFN were significant factors affecting SVR among diabetics, while female gender and viraemia were significant factors affecting SVR among non diabetics. Hepatic fibrosis and SOF/RBV significantly influenced SVR in both groups. Diabetic patients with CHC have worse liver biochemical profile, yet DM per se did not influence the virologic response to DAAs, however, some factors played roles in affecting SVR among them.

中文翻译：

---

与非糖尿病患者相比，接受直接抗病毒治疗时，慢性丙型肝炎病毒反应的糖尿病患者

丙型肝炎病毒（HCV）损害葡萄糖稳态，从而影响其临床表现和预后。成年 CHC 患者分为 2 组；糖尿病患者作为对照组，非糖尿病患者作为对照组。所有患者均接受了全面的临床评估、基本生化实验室测试，包括空腹血糖/糖化血红蛋白 (HbA1C) 和病毒学检测。他们接受了各种联合 DAA 治疗，并在治疗期间、治疗时和治疗结束后进行监测。糖尿病患者占 CHC 的 9.85%，与非糖尿病患者相比，其实验室检查结果普遍较差（转氨酶、血小板计数、Fib4 和肝脂肪变性显着升高），并且持续病毒学应答 (SVR) 较差（在索磷布韦 (SOF) + 聚乙二醇化药物中尤为明显）干扰素 (PegIFN) + 利巴韦林 (RBV)、SOF + RBV、SOF + 达卡他韦 (DAC)）。虽然DM对SVR没有显着影响，但Fib4和SOF+RBV+PEG-IFN是影响糖尿病患者SVR的显着因素，而女性性别和病毒血症是影响非糖尿病患者SVR的显着因素。肝纤维化和 SOF/RBV 显着影响两组的 SVR。患有CHC的糖尿病患者肝脏生化特征较差，但DM本身并不影响DAA的病毒学反应，但一些因素影响了其中的SVR。